|
Product Details:
Payment & Shipping Terms:
|
Product Name: | Peptide Tirzepatide | Appearance: | White Lyophilized Powder |
---|---|---|---|
CAS: | 2023788-19-2 | Warehouse: | US, EU, UK |
MOQ: | 1 Kit (10 Vials) | Reship Policy: | Yes We Have |
M.F.: | C225H348N48O68 | Grade: | Pharmaceutical Grade |
Multiple Dosages Available - Peptide Tirzepatide for Effective Glycemic Control
Product desciption:
Pregnancy Considerations: Available information on tirzepatide use in pregnant women is inadequate to evaluate for a drug-related risk of congenital disabilities and adverse maternal or fetal outcomes. A risk to the mother and fetus is associated with poorly controlled diabetes in pregnancy. In addition, increased incidences of external, visceral, and skeletal malformations have been observed in animal reproduction studies. Therefore, there may be risks to the fetus from exposure to tirzepatide during pregnancy.
Consequently, tirzepatide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Patients of childbearing age should be prescribed tirzepatide after discussing the possible teratogenic effects. Physicians should also discuss the initiation of contraception before prescribing tirzepatide. In addition, the efficacy of oral hormonal contraception declines while on tirzepatide therapy.
There should be shared decision-making on possibly changing the method of contraception to a non-oral route or utilizing barrier contraception for at least four weeks after initiation of tirzepatide therapy.
Breastfeeding Considerations: There is no information on tirzepatide in animal or human milk or its effects on the breastfed infant. Therefore, clinicians should consider the developmental and health benefits of breastfeeding, the mother's clinical need for tirzepatide, and potential adverse impacts on the breastfed infant from tirzepatide.
Tirzepatide is a large molecule with high molecular weight. Accordingly, the milk concentration is likely to be less, and absorption is unlikely because it is presumably partially destroyed in the infant's gastrointestinal tract. Therefore, until more clinical data become available, tirzepatide should be used cautiously during breastfeeding, especially in newborn or preterm infants.
Related products:
GH 10iu 191AA | GH Fragment 176-191 | Adipotide |
Melanotan II | Tirzepatide | Epithalon |
Growth hormone | KPV | Oxytocin 2 |
IGF1-LR3 | PT-141 | |
HCG 5000iu Livzlon brand | P21 peptide | GHK-CU |
HCG 5000iu | BPC-157 | Fox04 dri |
TB-500 | CJC-1295 | DSIP |
Hexarelin | HMG 75iu | AOD9604 |
Ipamorelin | Sermorelin | MGF |
Selank | Semaglutide | Peg-mgf |
Semax | Tesamorelin | EPO 3000iu |
Thymalin | Thymosin alpha | Follistatin 344 |
GHRP2 | GHRP6 | Kisspeptin-10 Peptide |
Gondorelin | IGF-1 DES | Dermorphin |
IGF-LR3 | Melanotan | ACE-031 |
Mots-C | Myostatin | AICAR |
Please contact us for more products |
Product Photos:
Certifications:
Company:
FAQ:
Contact Person: jason
Tel: +86 17792557883